Tel.: 514-340-8260 ext. 25284
or contact lab members:
Tel.: 514-340-8260 ext: 25251 

Dr. Anne Gatignol
Senior Investigator, Head of "Virus-Cell Interactions" Laboratory, Lady Davis Institute for Medical Research
Professor Department of Medicine, Division of Experimental Medicine; Department of Microbiology and Immunology, McGill University 
Dr. Gatignol’s Publications Indexed on PubMed
Dr. Anne Gatignol obtained a Pharmacist diploma and PhD in Microbiology from the University of Toulouse, France. She completed a first post-doctoral training in the department of Biochemistry at the George Washington University, Washington, DC, USA and a second at the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. She worked as a researcher at the Institut National de la santé et de la recherche médicale and the Cochin Institute, Paris, France. Now a senior investigator at the Lady Davis Institute for Medical Research, and full Professor at McGill University, her current focus is on various aspects of virology and molecular biology, specifically as applied to virus-cell interactions and to the development of RNA therapeutics against the human immunodeficiency virus (HIV) and SARS-Cov-2.
Major Research Activities
Dr. Gatignol’s research focuses on the control of the cellular responses to HIV infection, which enhance or inhibit viral replication. She characterized several cellular factors that contribute to the regulation of PKR during HIV replication in lymphocytes and astrocytes. Her work continues with the characterization of this regulation in primary lymphoid and myeloid cells that are the natural targets for HIV.

Dr. Gatignol’s lab also studies the interactions between viruses and the components of the RNA interference machinery. She characterized the relationship between TRBP and Dicer proteins in the RNA-induced silencing complex. She is analyzing the modifications of the RNAi pathway induced by the HIV, Zika and SARS-CoV-2 viruses and their pathological consequences.

Dr. Gatignol’s lab also develops RNA-based technologies to target HIV, SARS-CoV-2 and their cellular cofactors to inhibit viral replication. The aim of this project is to use the active anti-HIV molecules expressed on a lentiviral vector for use in gene therapy and to develop RNA therapeutics against SARS-CoV-2 to be used intransally as an antiviral treatment.

Recent Publications

Chen MJ, Gatignol A, Scarborough RJ. The discovery and development of RNA-based therapies for treatment of HIV-1 infection. Expert Opin. Drug Discov. 2023. 18:163-179.

Alpuche-Lazcano SP, Saliba J, Costa VV, Campolina-Silva GH, Marim FM, Ribeiro LS, Blank V, Mouland AJ, Teixeira MM, Gatignol A. Profound downregulation of neural transcription factor Npas4 and Nr4a family in fetal mice neurons infected with Zika virus. PLoS Negl. Trop. Dis. 2021. 1: e0009425.

Goguen RP, Del Corpo O, Malard CMG, Daher A, Alpuche-Lazcano SP, Chen MJ, Scarborough RJ, Gatignol A. Efficacy, accumulation and transcriptional profile of anti-HIV shRNAs expressed from human U6, 7SK and H1 promoters. Mol. Ther. Nucleic Acids. 2021. 23:1020-1034.

Del Corpo O, Goguen RP, Malard CMG, Daher A, Colby-Germinario S, Scarborough RJ, Gatignol A. A U1i RNA that enhances HIV-1 splicing with elongated recognition domain is an optimal candidate for combination HIV-1 gene therapy. Mol. Ther. Nucleic Acids. 2019. 18:815-830.

Radetskyy R, Daher A, Gatignol A. ADAR1 and PKR, interferon stimulated genes with clashing effects on HIV-1 replication. Cyt. Growth Factors Rev. 2018. 40:48-58.
Dr. Anne Gatignol is an internationally recognized scientist in the field of virology for her work on virus-cell interactions during HIV replication.

She was the first to clone the cDNA coding for the cellular protein TRBP and to characterize its function in the cell and during HIV replication. TRBP has important cellular functions in development, cell growth, regulation of innate cell response to infection and in RNA interference.

Her current projects involve the innate cell response to HIV infection, the relationship between HIV, Zika virus and the RNA interference pathway, as well as the development of RNA-based technologies to counteract HIV and SARS-CoV-2 replication.

She is involved in multiple collaborations domestically and throughout the world, including the United States, Australia, Brazil and Europe.

She is actively involved in undergraduate and graduate teaching in the Experimental Medicine and the Microbiology and Immunology programs at McGill University, where she coordinates the Viral Pathogenesis course.
Important Links
Support research at the Lady Davis Institute - Jewish General Hospital